联康生物科技集团(00690)发布中期业绩,净利润7595.5万港元,同比增长12.7%

智通财经
Aug 28, 2025

智通财经APP讯,联康生物科技集团(00690)发布2025年中期业绩,收益3.10亿港元,同比增长13.4%;净利润7595.5万港元,同比增长12.7%;每股基本盈利1.27港仙。

期内溢利同比增长,主要得益于集团销售渠道的扩张、对博固泰®日益增长的需求,以及市场对集团已上市药品的持续关注。这同时反映了集团专注于营运效率、严格成本控制及精准商业执行的战略成效,进一步巩固了其持续盈利增长与长期价值创造的发展轨迹。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10